HHLR Advisors’s Cytek Biosciences CTKB Stock Holding History

HHLR Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.1M	Hold	6,657,030	–	–	1.74%	9
2025 Q4	$33.6M	Hold	6,657,030	–	–	1.08%	9
2025 Q3	$23.1M	Hold	6,657,030	–	–	0.56%	15
2025 Q2	$22.6M	Hold	6,657,030	–	–	0.73%	14
2025 Q1	$26.7M	Hold	6,657,030	–	–	0.75%	15
2024 Q4	$43.2M	Hold	6,657,030	–	–	1.5%	14
2024 Q3	$36.9M	Hold	6,657,030	–	–	0.81%	15
2024 Q2	$37.1M	Hold	6,657,030	–	–	0.92%	13
2024 Q1	$44.7M	Hold	6,657,030	–	–	0.97%	16
2023 Q4	$60.7M	Hold	6,657,030	–	–	1.22%	15
2023 Q3	$36.7M	Hold	6,657,030	–	–	0.82%	17
2023 Q2	$56.9M	Sell	6,657,030 -1,046,484	-14%	-$9.39M	1.21%	16
2023 Q1	$70.8M	Sell	7,703,514 -981,016	-11%	-$10.6M	1.26%	15
2022 Q4	$88.7M	Sell	8,684,530 -72,500	-0.8%	-$974K	1.87%	12
2022 Q3	$129M	Hold	8,757,030	–	–	3.39%	9
2022 Q2	$94M	Hold	8,757,030	–	–	2.01%	13
2022 Q1	$94.4M	Hold	8,757,030	–	–	1.97%	12
2021 Q4	$143M	Hold	8,757,030	–	–	2.21%	11
2021 Q3	$187M	Buy	+8,757,030	New	+$206M	2.45%	11

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HHLR Advisors's CTKB Position: Q1 2026 in Review

HHLR Advisors held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 6,657,030 shares worth $29.1M. The position accounts for 1.74% of the portfolio, ranked #9.

HHLR Advisors first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $187M in Q3 2021. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

HHLR Advisors held 6,657,030 shares of Cytek Biosciences worth $29.1M as of Q1 2026.
HHLR Advisors left its Cytek Biosciences share count unchanged in Q1 2026.
Cytek Biosciences made up 1.74% of HHLR Advisors's portfolio in Q1 2026, its #9 holding.
HHLR Advisors first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
HHLR Advisors's Cytek Biosciences position peaked at $187M in Q3 2021.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on HHLR Advisors's 13F filing for Q1 2026, filed 15 May 2026.